Hope Foundation

ABSTRACTMDX2001 is a tetraspecific T-cell engager-expander antibody engineered to recognize four distinct antigens: cellular mesenchymal-epithelial transition factor (c-MET) and trophoblast antigen 2 (TROP2) to direct T cells to tumor cells, CD3 to activate T cells, and CD28 to enhance T-cell survival and proliferation. MDX2001 has demonstrated potent antitumor activity in nonclinical studies over a wide range of tumor types. Here, we present the protocol design for study MDX-2001–101, a multicenter, open-label, phase I/IIa clinical trial designed to evaluate the safety, tolerability, and antitumor effects of MDX2001 in patients with advanced solid tumors. The study comprises a phase Ia dose escalation guided by a Bayesian optimal interval design with a targeted maximum tolerated dose toxicity rate of 30%, a phase Ib dose expansion, and a phase IIa indication expansion.

Let L be a C-lattice. In this paper, we associate to each C-lattice L, an undirected simple graph P(L) in which the vertex set is the collection of all non-trivial practice, for "even more basic," it can be omitted if we assume a very simple environment where ASCII or a default proper elements of L and two different members a and b of vertex set of P(L) are adjacent if and only compatible encoding is used. The symbols used (`∨`) are part of HTML entities and should render. 3. if a v b (a join b) is a prime element of L. Also, we obtain the interrelationship between some algebraic properties of C-lattice L and graph-theoretic properties of P(L).

Abstract Background We previously reported that a major portion of trinucleotide two-repeat units (TTUs) are sites of unequal crossover and consequent colonization, that are massively spread and shared across the genomes of human and several other primates. These sites underscore the preference of AT- over CG-rich sequences, as recombination sites. Methods Here we extended our study to dinucleotides of AT/TA and CG/GC. An algorithm was designed to extract genomic regions with a higher probability of recombination. To this end, the algorithm consisted of dinucleotide 3-repeat units (D3Us), a portion of which was hypothesized to be the basic overlapping units, resulting from unequal crossover between dinucleotide two-repeat units (D2Us). We mapped TATATA, ATATAT, CGCGCG, and GCGCGC across the human genome, and analyzed their colonization (distance between consecutive D3Us < 500 bp). We also studied several colonies of various sizes in up to 100 vertebrates, using the UCSC and ENSEMBL Genome Browsers. Results We found 3,989,861 AT/TA and 95,849 CG/GC D3Us across the human genome, the majority of which resided in over 480,000 colonies, ubiquitously spread along all chromosomes. The AT/TA colonies were significantly larger and more intricate than CG/GC colonies. These colonies were mainly specific to, or of their largest size in human. D2Us and D3Us were the primary sites of unequal crossover in these colonies, resulting in the emergence of primary recombinants (overlaps among AT/TA repeats), ranging from 5- to 15-bp, and a vast repertoire of secondary recombinants (recombination among pure and primary recombinants), and eventually, colonies of exceeding intricacy and significance, based on Poisson distribution. Conclusion We report ubiquitous and intricate colonies of exceeding significance, in which D2Us and D3Us were the primary sites of unequal crossover and recombination. Across vertebrates, these colonies reached their maximum size in human. It is plausible that minimal DNA repeat sequences, such as D2Us, D3Us, and TTUs, mark recombination a ubiquitous rule across the human genome. This phenomenon may transform our perception of recombination, its magnitude, and biological and evolutionary consequences.

Management of oligometastatic non-small cell lung cancer (OM-NSCLC) has changed considerably in recent years, as these patients were found to have better survival with systemic therapy followed by consolidative radiation. Stereotactic body radiotherapy (SBRT), characterized by high doses of radiation delivered in a limited number of fractions, has been shown to have improved local control compared to conventionally fractionated radiation in early-stage lung cancer, but its use in large tumors, ultra-central tumors, or mediastinal nodal regions is limited due to concerns of toxicity to nearby serial mediastinal structures. Recent improvements in image guidance and fast replanning allow adaptive radiotherapy to be used to personalize treatment to the patient's daily anatomy and ensure accurate dose delivery to the tumor while minimizing dose and toxicity to normal. Adaptive SBRT can expand its use into ultra-central tumors that otherwise may not be amenable to SBRT or enable alternative fractionation schedules such as personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) with one-month intervals between fractions. In this case, we report a patient initially presenting with bulky OM-NSCLC of the left lung and mediastinum with an isolated left femur metastasis who was referred for consolidative radiotherapy after systemic therapy. We demonstrate how CT-guided online adaptive radiotherapy to the lung and mediastinum can be used despite the long time interval between treatments. In addition, adaptive plans lead to a substantial decrease in the heart dose, with moderate decreases in other organs compared to non-adaptive plans. This case demonstrates the feasibility of using adaptive radiotherapy for PULSAR of ultra-central OM-NSCLC.

Low-titer group O whole blood (LTOWB) for treatment of hemorrhagic shock sometimes necessitates transfusion of RhD-positive units due to short supply of RhD-negative LTOWB. Practitioners must choose between using RhD-positive LTOWB when RhD-negative is unavailable against the risk to a female of childbearing potential of becoming RhD-alloimmunized, risking hemolytic disease of the fetus and newborn (HDFN) in future children, or using component therapy with RhD-negative red cells. This survey asked females with a history of red blood cell (RBC) alloimmunization about their risk tolerance of RhD alloimmunization compared to the potential for improved survival following transfusion of RhD-positive blood for an injured RhD negative female child. A survey was administered to RBC alloimmunized mothers. Respondents were eligible if they were living in the United States with at least one red cell antibody known to cause HDFN and if they had at least one RBC alloimmunized pregnancy. Responses from 107 RBC alloimmmunized females were analyzed. There were 32/107 (30%) with a history of severe HDFN; 12/107 (11%) had a history of fetal or neonatal loss due to HDFN. The median (interquartile range) absolute improvement in survival at which the respondents would accept RhD-positive transfusions for a female child was 4% (1%-14%). This was not different between females with and without a history of severe or fatal HDFN (p = .08 and 0.38, respectively). Alloimmunized mothers would accept the risk of D-alloimmunization in a RhD-negative female child for improved survival in cases of life-threatening bleeding.

Glycogen storage disease type Ib (GSD Ib, biallelic variants in SLC37A4) is a rare disorder of glycogen metabolism complicated by neutropenia/neutrophil dysfunction. Since 2019, the SGLT2-inhibitor empagliflozin has provided a mechanism-based treatment option for the symptoms caused by neutropenia/neutrophil dysfunction (e.g. mucosal lesions, inflammatory bowel disease). Because of the rarity of GSD Ib, the published evidence on safety and efficacy of empagliflozin is still limited and does not allow to develop evidence-based guidelines. Here, an international group of experts provides 14 best practice consensus treatment recommendations based on expert practice and review of the published evidence.We recommend to start empagliflozin in all GSD Ib individuals with clinical or laboratory signs related to neutropenia/neutrophil dysfunction with a dose of 0.3–0.4 mg/kg/d given as a single dose in the morning. Treatment can be started in an outpatient setting. The dose should be adapted to the weight and in case of inadequate clinical treatment response or side effects. We strongly recommend to pause empagliflozin immediately in case of threatening dehydration and before planned longer surgeries. Discontinuation of G-CSF therapy should be attempted in all individuals. If available, 1,5-AG should be monitored. Individuals who have previously not tolerated starches should be encouraged to make a new attempt to introduce starch in their diet after initiation of empagliflozin treatment. We advise to monitor certain safety and efficacy parameters and recommend continuous, alternatively frequent glucose measurements during the introduction of empagliflozin. We provide specific recommendations for special circumstances like pregnancy and liver transplantation.

Abstract CG-rich trinucleotide short tandem repeats (STRs) are linked with human cognition and various neurodevelopmental, neurological, and movement disorders. However, the fundamental two-repeat units of these STRs remain unexplored. On a genome-wide scale, here we mapped the two-repeat units of all combinations of CG-rich trinucleotides in human. We found 81,118 colonies (distance between each unit <500 bp). Subsequently, we performed a comparative genomics study of several large and medium-sized colonies of significant occurrence based on Poisson distribution, in other primates and mouse. We discovered that some of those colonies were shared, with extensive dynamicity, as phylogenetically distant as in mouse. We detected pure units and units that were overlaps of those pure units across the colonies, indicative of unequal crossing over and recombination at those units. We provide example models of some of the potential evolutionary implications of the colonies, such as mechanisms for the emergence and propagation of non-coding RNAs, as well as a defense system against transposable elements, through recombination-coupled inactivating mutations and methylation. In conclusion, we report extensively dynamic trans-species colonies of CG-rich trinucleotide two-repeat units, and indication of crossing over and recombination at those units. Whereas the bulk of literature supports the hypothesis that recombination hotspots rarely (if at all) occur at the same locus between human and chimpanzee, here we propose that sharing such loci may extend beyond primates, and include mouse. Based on the ubiquity, abundance, significant occurrence, and envisioned events and mechanisms associated with the identified colonies, we predict the identified colonies of phenomenal biological and evolutionary consequences.